NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?

Bookmark and Share
Published: 13 Jun 2019
Views: 338
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Prof Matthew Galsky talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the NILE trial.

He give a brief overview of the trial, and explains how it could define the new standard of care in this setting.